Kopran Ltd. (BSE: 524280) is a Mumbai, Maharashtra-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹1,309 Cr, it ranks #1,450 by market cap among the 6,137 Indian listed companies on FinBizNet, and #44 of 86 in Medicinal Chemicals and Botanical Products. At ₹246.30 (as of 25 Oct 2026), the share price is 16.7% below its 52-week high of ₹295.83 and 130.2% above its 52-week low of ₹107.00. The share price is up 47.3% over one year and up 23.9% over three months.
| Current Price | ₹246.30 |
|---|---|
| Market Cap | ₹1,309 Cr |
| BSE Code | 524280 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 52.3 |
| Return on Equity | 4.91% |
| Return on Assets | 4.31% |
| 52-Week Range | ₹107.00 – ₹295.83 |
| 1-Year Price Change | +47.3% |
| 3-Month Price Change | +23.9% |
| Beta (1Y) | 1.16 |
| Dividend Yield | 1.08% |
| Headquarters | Mumbai, Maharashtra |
| Website | www.kopran.com |
| Revenue | ₹154 Cr |
|---|---|
| Net Profit | ₹7 Cr |
| Net Margin | 4.4% |
| EPS (Basic) | ₹1.39 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Kopran Limited, an integrated pharmaceutical company, engages in the development, manufacture and marketing of active pharmaceutical ingredients and finished dosage forms in India and internationally. The company offers its products in various dosage forms, including tablets, capsules, syrups, dry powder, suspension, and injectables, as well as branded and generic formulations. It also provides drugs in the categories of macrolide, antibacterial, anticonvulsant, anti-hypertensive, anti- helminthics, anti-acne, anti-infective, anti-thrombotic, sterile carbapenem, urological, neuromodulator, antidiabetic, pain management, neuromodular, gastroenterology, and cardiovascular. In addition, the company offers drugs for erectile dysfunction, antiallergics, respiratory, oncology, central nervous system, antiprotozoal, anthelmintics, antipeptic ulcer and gut, and others. Kopran Limited was incorporated in 1958 and is based in Mumbai, India.
1. Pharmaceuticals Business-This segment engages in the manufacture and sale of finished dosage forms and active pharmaceutical ingredients. 2. Consumer Care-This segment consumer healthcare products, which include family toothpaste under the SPARKLE brand; body deodorants and deo talcs; and face moisturizers and face wash products. 3. OTC Products-0 4. Trading Products-This segment manufactures and sells over-the-counter products.
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,21,995 Cr | 36.4 | 14.72% | ₹15,300 Cr | +5.4% |
| Zydus Lifesciences Ltd | ₹1,12,020 Cr | 22.2 | 18.32% | ₹8,017 Cr | +14.7% |
| Laurus Labs Ltd | ₹1,11,310 Cr | 125.3 | 17.74% | ₹2,026 Cr | +125.7% |
| Cipla Limited | ₹1,07,048 Cr | 27.6 | 11.74% | ₹7,119 Cr | -14.7% |
| Dr.Reddys Lab | ₹1,02,611 Cr | 24.1 | 11.52% | ₹8,698 Cr | -0.9% |
| Aurobindo Pharma Ltd. | ₹95,910 Cr | 26.8 | 9.93% | ₹9,150 Cr | +41.7% |
| Mankind Pharma | ₹93,977 Cr | 48.7 | 12.45% | ₹4,031 Cr | -9.9% |
| Lupin Ltd | ₹89,426 Cr | 16.6 | 26.91% | ₹8,277 Cr | -1.1% |
| Kopran Ltd. | ₹1,309 Cr | 52.3 | 4.91% | ₹154 Cr | +47.3% |
Listed by market capitalisation. Ratios are shown for context only.
Kopran Ltd. is trading at ₹246.30, with a market capitalisation of ₹1,309 Cr.
Kopran Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Kopran Ltd. has a P/E of 52.3 and a return on equity of 4.91%.
Kopran Ltd. is listed on the BSE under the scrip code 524280.
Kopran Ltd.'s share price is up 47.3% over one year and up 23.9% over three months. Its 52-week range is ₹107.00 to ₹295.83.
In Q1 FY27, Kopran Ltd. reported revenue of ₹154 Cr and net profit of ₹7 Cr, with basic EPS of ₹1.39 (consolidated, parsed from the company's exchange filing).
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.